Clinical Trial Update: A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

View source ↗

Summary

Long-term follow-up study in severe Hemophilia A patients who previously received BMN 270; enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BMN 270

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hemophilia A | Status: ENROLLING_BY_INVITATION